GLP-1 for weight loss

GLP 1 drugs can help you lose 10% to 22% of your body weight. That range depends on which drug you take, what dose you reach, and whether you have type 2 diabetes. In the STEP 1 trial, people on semaglutide 2.4 mg (Wegovy) lost an average of 14.9% of their starting weight over 68 weeks. In SURMOUNT 1 trial, people on highest dose of tirzepatide (Zepbound) lost about 22.5%.

Those are clinical trial numbers. In real life, most people on semaglutide lose somewhere around 10% to 14% in first year. That is still more weight loss than any other class of medication has produced for obesity. And a 10% drop in body weight is enough to lower your blood pressure, improve your blood sugar, reduce joint pain, and cut your risk of heart disease.

This article goes through how GLP-1 drugs actually produce weight loss, what research says about each drug, who qualifies, and what experience looks like month by month.

How do GLP1 drugs make you lose weight?

They reduce your appetite. That is main mechanism. These drugs copy a hormone called glucagon like peptide 1 that your gut releases after you eat. The natural version lasts about two minutes before an enzyme called DPP 4 destroys it. The drug version is engineered to resist that enzyme, so it stays active for days.

Two things happen when drug activates GLP1 receptors in your brain and gut. First, it slows gastric emptying. Food sits in your stomach longer, which means you feel full for a longer stretch after a meal. Second, it acts on hypothalamus, which is part of your brain that regulates hunger. People on these drugs often describe it as "food noise" going quiet. You stop thinking about your next meal moment you finish current one.

The weight loss itself comes from eating less. You're not burning more calories. You're consuming fewer because your appetite is genuinely reduced. Some people eat 20% to 30% fewer calories per day without actively trying.

How much weight can you expect to lose?

It varies by drug. Here are numbers from largest trials, so you can see what each medication actually delivered.

Semaglutide 2.4 mg (Wegovy) produced an average loss of 14.9% of body weight at 68 weeks in people without type 2 diabetes. In people with diabetes, the average was closer to 9.6%. About half of non diabetic participants lost 15% or more. About one in three lost 20% or more.

Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) works on two receptors instead of one, GLP 1 and GIP. In the SURMOUNT 1 trial, the highest dose produced an average loss of about 22.5% at 72 weeks. Even lowest dose (5 mg) produced about 15%.

Liraglutide 3.0 mg (Saxenda) is a daily injection that produces more modest results, typically 5% to 8% body weight loss. It was the first GLP1 approved for weight loss and is still used, but newer drugs outperform it.

Dulaglutide (Trulicity) is approved for diabetes, not for weight loss. It produces some weight reduction as a secondary effect, usually around 2 to 4 kg more than placebo.

A 2025 meta-analysis published in Diabetes Care pooled data from 47 randomized trials covering over 23,000 patients. It confirmed that GLP-1 receptor agonists as a class consistently reduce weight, BMI, and waist circumference compared to placebo. Higher doses and longer treatment durations led to greater losses.

If you want a detailed breakdown of every FDA approved option and how they compare head to head, we cover that in GLP-1 drugs for weight loss.

Which GLP-1 is best for weight loss?

There is no single answer. But if you're going purely by how much weight people lose in clinical trials, tirzepatide at its highest dose produces most weight loss of any GLP-1 drug currently available. Semaglutide 2.4 mg comes second. Everything else trails behind.

That said, "best" depends on more than trial averages. Your doctor will think about whether you have diabetes, what your insurance covers, whether you're comfortable with injections, how you respond to side effects, and what other medications you're already taking.

Some people do better on a mid range dose of one drug than maximum dose of another. Some people switch between drugs partway through treatment because their body responds differently over time.

We go deeper into these comparisons, including real world considerations beyond trial data, in which GLP-1 is best for weight loss.

Can you use GLP-1 drugs for weight loss if you don't have diabetes?

Yes. Wegovy and Zepbound are both FDA approved specifically for chronic weight management in adults without diabetes. You need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight related health condition. That includes things like high blood pressure, high cholesterol, prediabetes, sleep apnea, or joint problems from extra weight.

The biggest weight loss trials for these drugs were actually conducted in people without diabetes. STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide both enrolled primarily non diabetic participants. People without diabetes tend to lose slightly more weight on these drugs than people with diabetes, probably because diabetes itself causes metabolic changes that make fat loss harder.

If you're in this situation and wondering about your specific options, our article on GLP-1 weight loss without diabeteswalks through the eligibility requirements, how to talk to your doctor about it, and what to expect.

Some people also ask specifically about getting Mounjaro for weight loss even though it's technically a diabetes drug. There are pathways for that, and we cover them in how to get Mounjaro without diabetes.

What does the weight loss look like month by month?

Most people notice their appetite drop within first week or two. The scale usually starts moving within first month, though it's common to lose just a couple of pounds initially because you're on a low starter dose.

Months two through six are when weight loss picks up. You're gradually titrating to higher doses during this period. For semaglutide, the escalation from 0.25 mg to full 2.4 mg takes about 16 to 20 weeks. For tirzepatide, the climb from 2.5 mg to whatever your maintenance dose ends up being takes a similar amount of time.

Months six through twelve are typically when the biggest drop happens. Most of weight loss occurs in first year.

After that, the weight usually plateaus. This doesn't mean drug stopped working. It means your body reached a new equilibrium between calories in and calories out at your current weight. The STEP 5 trial followed people on semaglutide for two full years and found they maintained an average loss of about 15.2% from baseline all way through week 104.

But here is part most people don't hear enough about. When patients in STEP 1 extension study stopped semaglutide after 68 weeks, they regained roughly two thirds of weight they had lost within next year. Appetite came back. The biological drivers of hunger returned to their pre treatment levels. This is why most doctors now treat GLP-1 therapy for obesity as a long term commitment rather than a short course.

If you want to see realistic timelines and outcomes, including what happens at three month, six-month, and twelve month marks, we go into that in GLP-1 weight loss before and after.

What about dosing for weight loss specifically?

GLP-1 drugs are always started low and increased gradually. This slow titration reduces nausea and other gastrointestinal side effects, which are most common in early weeks and during dose bumps.

For Wegovy, you start at 0.25 mg weekly and step up every four weeks: 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg. The whole escalation takes about four to five months.

For Zepbound, you start at 2.5 mg weekly for four weeks, then move to 5 mg. From there, your doctor can increase by 2.5 mg increments every four weeks up to 15 mg, depending on how you respond and what you tolerate.

The dose you end up on matters for how much weight you lose. In SURMOUNT trials, tirzepatide at 15 mg produced roughly 7 percentage points more weight loss than tirzepatide at 5 mg. But higher doses also come with more side effects. Some people find their sweet spot at a mid range dose and stay there.

Your doctor can help you figure out which dose gives you best tradeoff. We break down the specifics, including titration schedules and what each dose level delivers, in GLP-1 dosage for weight loss.

What happens to your body beyond the scale?

When you lose 15% or more of your body weight, your body goes through changes that go well beyond what scale shows.

Facial fat loss is one of most visible. People call it "Mounjaro face." When you lose fat everywhere, you lose it from your face too. For some people, especially those who lose weight quickly, the face can look noticeably thinner or more hollow. This is a cosmetic concern, not a medical one. It tends to stabilize once your weight levels off.

Some people notice temporary hair thinning during rapid weight loss. This is called telogen effluvium. It is triggered by physical stress of fast weight change, not by drug itself. It almost always reverses on its own within a few months.

Muscle loss is a real concern. Studies suggest 25% to 40% of weight lost on GLP-1 drugs can be lean mass rather than fat. This is why doctors recommend strength training and high protein intake while on these drugs. Aiming for at least 1.0 to 1.2 grams of protein per kilogram of body weight daily can help protect your muscles.

On the positive side, the metabolic improvements tend to be substantial. Blood pressure drops. Blood sugar improves, sometimes enough that people with prediabetes move back into normal range. Cholesterol and triglyceride levels often improve. Joint pain from carrying extra weight eases. Sleep apnea symptoms may reduce or resolve. And plenty of people report sleeping better and having more energy during day.

Who should not use GLP-1 drugs for weight loss?

These drugs are not for everyone. There are clear contraindications.

You should not take a GLP-1 drug if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. All GLP-1 drugs carry a boxed warning about this based on findings in animal studies.

People with a history of pancreatitis should use these drugs carefully and with close monitoring. GLP-1 drugs slow gastric emptying, so if you have severe gastroparesis (where stomach already empties too slowly), they can make that worse.

You need to stop these drugs at least two months before a planned pregnancy. They are not approved for use during pregnancy.

If you have a history of eating disorders, the appetite suppression effects of these medications need to be discussed carefully with your provider. The line between helpful appetite reduction and unhealthy restriction is something to watch.

For most adults who meet BMI criteria and don't have a contraindication, GLP-1 drugs have a well established safety profile backed by years of clinical trial data and real world use.